Literature DB >> 1614056

Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction.

L S Weisberg1, P B Kurnik, B R Kurnik.   

Abstract

Radiocontrast-induced nephropathy (RCIN) is a common cause of acute renal failure in hospitalized patients. Renal vasoconstriction figures prominently in the proposed pathogenesis of RCIN based on animal experiments. Prior human studies examining renal hemodynamic changes after contrast medium (CM) injection are inconclusive. No previous study of animals or humans has established a relationship between CM-associated renal hemodynamic changes and the subsequent development of RCIN. In the present study, we examined the renal hemodynamic effects of CM in patients at high risk of RCIN. In addition, we related those effects to the subsequent development of RCIN. Using renal vein thermodilution catheters, we measured renal blood flow (RBF) in 12 patients with chronic renal failure [serum creatinine (SCr) greater than or equal to 159 mumol/liter] during ionic CM injection for cardiac catheterization. We made measurements at the start of the procedure (t = 0), before the ventriculogram (t = 5), after the ventriculogram (t = 15), and after the coronary angiogram (t = 65). We measured SCr at t = 0 and again 24 and 48 hours later. Mean RBF for the group tended to increase after the ventriculogram, and increased significantly by t = 65 (P less than 0.005 vs. t = 0). When examined by individual patient, RBF fell below baseline in three patients (30%) at t = 15, but rose above baseline again by t = 65. Only one patient (8.3%) had a fall in RBF below baseline at t = 65. RCIN (defined as an increase in SCr greater than or equal to 25% above baseline) developed in six patients (50%) within 48 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614056     DOI: 10.1038/ki.1992.206

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug.

Authors:  Farahnak Assadi
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

2.  Changes in intrarenal oxygenation as evaluated by BOLD MRI in a rat kidney model for radiocontrast nephropathy.

Authors:  P V Prasad; A Priatna; K Spokes; F H Epstein
Journal:  J Magn Reson Imaging       Date:  2001-05       Impact factor: 4.813

3.  Effect of renin-angiotensin-aldosterone system blockade therapy on incidence of contrast-induced nephropathy in patients with chronic kidney disease.

Authors:  Christin Spatz; Lawand Saadulla; Apurva Lapsiwala; Amin Parhizgar; Nasrollah Ghahramani
Journal:  Iran J Kidney Dis       Date:  2012-11       Impact factor: 0.892

4.  N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.

Authors:  V O Gomes; C E Poli de Figueredo; P Caramori; R Lasevitch; L C Bodanese; A Araújo; A P Röedel; A P Caramori; F S Brito; H G Bezerra; P Nery; A Brizolara
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

5.  Atrial natriuretic peptide for the prevention of contrast-induced nephropathy: what's old is new but at the right dose and duration of therapy!

Authors:  Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2009-03-24       Impact factor: 24.094

Review 6.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

7.  Obesity is not associated with contrast nephropathy.

Authors:  Navin Jaipaul; Rendell Manalo; Seyed-Ali Sadjadi; James McMillan
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

8.  Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat.

Authors:  Y Agmon; H Peleg; Z Greenfeld; S Rosen; M Brezis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Contrast-Induced Nephropathy Is Less Common in Patients with Good Coronary Collateral Circulation.

Authors:  Eyup Avci; Tarik Yildirim; Hasan Kadi
Journal:  Cardiorenal Med       Date:  2017-08-04       Impact factor: 2.041

10.  Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide.

Authors:  Ketab E Al-Otaibi; Abdulrahman M Al Elaiwi; Mohammad Tariq; Abdulrahman K Al-Asmari
Journal:  Oxid Med Cell Longev       Date:  2012-10-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.